Skip to main content

Advertisement

SpringerLink
Log in

Beyond haematuria in uro oncology: imaging biomarkers lag behind needs

  • Focus on
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Higashihara E, Nishiyama T, Horie S, Marumo K, Mitarai T, et al.; Working Group for the Creation of Hematuria Guidelines. Hematuria: definition and screening test methods. Int J Urol 2008;15:281–4.

    Article  PubMed  Google Scholar 

  2. Edwards TJ, Dickinson AJ, Natale S, Gosling J, McGrath JS. A prospective analysis of the diagnostic yield resulting from the attendance of 4020 patients at a protocol-driven haematuria clinic. BJU Int 2006;97:301–5.

    Article  PubMed  Google Scholar 

  3. O’Connor OJ, McSweeney SE, Maher MM. Imaging of hematuria. Radiol Clin North Am 2008;46:113–32.

    Article  PubMed  Google Scholar 

  4. Shirodkar SP, Lokeshwar VB. Bladder tumor markers: from hematuria to molecular diagnostics—where do we stand? Expert Rev Anticancer Ther 2008;8:1111–23.

    Article  PubMed  CAS  Google Scholar 

  5. Mishriki SF, Nabi G, Cohen NP. Diagnosis of urologic malignancies in patients with asymptomatic dipstick hematuria: prospective study with 13 years’ follow-up. Urology 2008;71:13–6.

    Article  PubMed  Google Scholar 

  6. Choyke PL. Radiologic evaluation of hematuria: guidelines from the American College of Radiology’s appropriateness criteria. Am Fam Physician 2008;78:347–52.

    PubMed  Google Scholar 

  7. Larson SM, Schöder H. Advances in positron emission tomography applications for urologic cancers. Curr Opin Urol 2008;18:65–70.

    Article  PubMed  Google Scholar 

  8. Jadvar H, Quan V, Henderson RW, Conti PS. [F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. Int J Clin Oncol 2008;13:42–7.

    Article  PubMed  Google Scholar 

  9. Bouchelouche K, Oehr P. Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review. J Urol 2008;179:34–45.

    Article  PubMed  CAS  Google Scholar 

  10. Scher B, Seitz M, Albinger W, Tiling R, Scherr M, Becker HC, et al. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 2007;34:45–53.

    Article  PubMed  Google Scholar 

  11. Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A, et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35:253–63.

    Article  PubMed  Google Scholar 

  12. Schiavina R, Scattoni V, Castellucci P, Picchio M, Corti B, Briganti A, et al. (11)C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 2008;54:392–401.

    Article  PubMed  Google Scholar 

  13. Soloviev D, Fini A, Chierichetti F, Al-Nahhas A, Rubello D. PET imaging with 11C-acetate in prostate cancer: a biochemical, radiochemical and clinical perspective. Eur J Nucl Med Mol Imaging 2008;35:942–9.

    Article  PubMed  Google Scholar 

  14. Vāvere AL, Kridel SJ, Wheeler FB, Lewis JS. 1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med 2008;49:327–34.

    Article  PubMed  CAS  Google Scholar 

  15. Schiepers C, Hoh CK, Nuyts J, Seltzer M, Wu C, Huang SC, et al. 1-11C-acetate kinetics of prostate cancer. J Nucl Med 2008;49:206–15.

    Article  PubMed  CAS  Google Scholar 

  16. Morris MJ, Scher HI. (11)C-acetate PET imaging in prostate cancer. Eur J Nucl Med Mol Imaging 2007;34:181–4.

    Article  PubMed  Google Scholar 

  17. Kotzerke J, Linné C, Meinhardt M, Steinbach J, Wirth M, Baretton G, et al. [1-(11)C]acetate uptake is not increased in renal cell carcinoma. Eur J Nucl Med Mol Imaging 2007;34:884–8.

    Article  PubMed  CAS  Google Scholar 

  18. Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gönen M, Ruan S, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 2007;8:304–10.

    Article  PubMed  CAS  Google Scholar 

  19. Schuster DM, Votaw JR, Nieh PT, Yu W, Nye JA, Master V, et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 2007;48:56–63.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Radiological Sciences, University of Milan, Unit of Nuclear Medicine, San Paolo Hospital, Via Antonio di Rudinì, 8, 20142, Milan, Italy

    Giovanni Lucignani

Authors
  1. Giovanni Lucignani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni Lucignani.

Additional information

“Focus on …” abridgements aim to highlight papers published within the past year and draw extensively on the texts and summaries of the articles referenced. Less recent citations are also included when deemed useful to provide background information on the topic reviewed.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lucignani, G. Beyond haematuria in uro oncology: imaging biomarkers lag behind needs. Eur J Nucl Med Mol Imaging 36, 152–157 (2009). https://doi.org/10.1007/s00259-008-0993-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-008-0993-9

Keywords

Search

Navigation